Linezolid 1a Pharma (Linezolid)

Linezolid is an oxazolidinone antibiotic that inhibits protein synthesis in Gram‑positive bacteria.

• Gram‑positive bacterial infections: effective against a broad range of susceptible organisms, reducing infection severity.
• Methicillin‑resistant Staphylococcus aureus (MRSA): provides an alternative therapy when β‑lactams are ineffective.
• Vancomycin‑resistant Enterococcus (VRE): offers treatment for infections caused by resistant enterococci.
• Community‑acquired pneumonia: used when typical pathogens include resistant Gram‑positive strains.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing the formation of the initiation complex required for protein synthesis. By blocking the early stage of translation, it halts bacterial growth without affecting human ribosomes, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms. The binding site is distinct from those of other antibiotic classes, which reduces cross‑resistance. The inhibition is reversible, allowing normal cellular functions to resume after drug removal.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often reported.
• Diarrhea: loose stools may occur.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste sensation in the mouth.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: nerve damage causing tingling or numbness.
• Serotonin syndrome: risk when combined with serotonergic agents, presenting with agitation, hyperreflexia, and fever.
• Lactic acidosis: buildup of lactate leading to metabolic disturbance.
• Optic neuropathy: visual impairment due to optic nerve damage.

When prescribing Linezolid, clinicians should observe several safety considerations to minimize risk.

• Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia.
• Assess liver function: evaluate hepatic enzymes before and during therapy.
• Avoid serotonergic drugs: concurrent use with SSRIs, MAOIs, or tramadol may precipitate serotonin syndrome.
• Adjust in renal impairment: dose may need modification in severe kidney dysfunction.
• Pregnancy and lactation: use only if benefits outweigh potential unknown risks.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Linezolid interacts with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Serotonergic agents (SSRIs, SNRIs, MAO inhibitors, tramadol): risk of serotonin syndrome.
• Rifampin: induces metabolism, markedly reducing linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: increased bleeding risk due to platelet effects.
• Warfarin: may alter INR, requiring dose adjustment.
• Antacids containing magnesium or aluminum: can decrease absorption of linezolid.